ArticleBritish journal of cancer2014
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.
Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Genomics of lethal prostate cancer at diagnosis and castration resistance.The Journal of clinical investigation · 2020Trial
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.The New England journal of medicine · 2015Trial
- Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.The Journal of clinical investigation · 2026Article
- TLN1: an oncogene associated with tumorigenesis and progression.Discover oncology · 2024Review
- Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples.Journal of clinical laboratory analysis · 2024Article
- Identification of Newcastle disease virus P-gene editing using next-generation sequencing.The Journal of veterinary medical science · 2020Article
- Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA.Diagnostics (Basel, Switzerland) · 2019Article
- Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.British journal of cancer · 2018Article
- The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group.NPJ breast cancer · 2017Article
- Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.Oncotarget · 2016Article
- Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.Diagnostic pathology · 2016Article
- Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges.Molecular medicine (Cambridge, Mass.) · 2016Article
- Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Translational oncogenomics · 2015Review
- The promise of circulating tumor cell analysis in cancer management.Genome biology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPredictive biomarker development is a key challenge for novel cancer therapeutics. We explored the feasibility of next-generation sequencing (NGS) to validate exploratory genomic biomarkers that impact phase I trial selection.
methodsWe prospectively enrolled 158 patients with advanced solid tumours referred for phase I clinical trials at the Royal Marsden Hospital (October 2012 to March 2013). After fresh and/or archived tumour tissue were obtained, 93 patients remained candidates for phase I trials. Results from tumour sequencing on the Illumina MiSeq were cross-validated in 27 out of 93 patients on the Ion Torrent Personal Genome Machine (IT-PGM) blinded to results. MiSeq validation with Sequenom MassARRAY OncoCarta 1.0 (Sequenom Inc., San Diego, CA, USA) was performed in a separate cohort.
resultsWe found 97% concordance of mutation calls by MiSeq and IT-PGM at a variant allele frequency ⩾13% and ⩾500 × depth coverage, and 91% concordance between MiSeq and Sequenom. Common 'actionable' mutations involved deoxyribonucleic acid (DNA) repair (51%), RAS-RAF-MEK (35%), Wnt (26%), and PI3K-AKT-mTOR (24%) signalling. Out of 53, 29 (55%) patients participating in phase I trials were recommended based on identified actionable mutations.
conclusionsTargeted high-coverage NGS panels are a highly feasible single-centre technology well-suited to cross-platform validation, enrichment of trials with molecularly defined populations and hypothesis testing early in drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.